FTC Notes Decline In Pay-For-Delay Drug Patent Settlements
The U.S. Federal Trade Commission reported Wednesday that pay-for-delay patent settlements between brand and generic-drug manufacturers declined from 2014 to 2015, continuing a sharp decline of such deals following the high...To view the full article, register now.
Already a subscriber? Click here to view full article